Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC)

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 3, 2011, Pages 753-761

  Cho, Eun Yoon ^a   Chang, Myung Hee ^a   Choi, Yoon La ^a   Lee, Jeong Eon ^a   Nam, Seok Jin ^a   Yang, Jung Hyun ^a   Park, Yeon Hee ^a   Ahn, Jin Seok ^a   Im, Young Hyuck ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

BRCA1; EGFR; Relapse free survival; Triple negative breast cancer

Indexed keywords

BRCA1 PROTEIN; CAPECITABINE; CAVEOLIN 1; CYTOKERATIN 14; CYTOKERATIN 17; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PLATINUM COMPLEX; PROTEIN P53; STEM CELL FACTOR RECEPTOR; TAXANE DERIVATIVE; VASCULOTROPIN;

ADULT; AGE; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PLEURA METASTASIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENCE RISK; RELAPSE FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; SOFT TISSUE METASTASIS; THORAX METASTASIS; THORAX WALL; TRIPLE NEGATIVE BREAST CANCER;

ADULT; ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GUIDELINES AS TOPIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PALLIATIVE CARE; RECEPTOR, EPIDERMAL GROWTH FACTOR; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053606688     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1548-x     Document Type: Article

References (38)

1. CM Perou T Sørlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen O Fluge A Pergamenschikov C Williams SX Zhu PE Lønning Al Børresen-Dale PO Brown D Botstein 2000 Molecular portraits of human breast tumours Nature 406 747 752 10963602 10.1038/35021093 1:CAS:528:DC%2BD3cXmt1CnsLw%3D
2. EA Rakha SE Elsheikh MA Aleskandarany HO Habashi AR Green DG Powe ME El-Sayed A Benhasouna JS Brunet LA Akslen R Blamey JS Reis-Filho WD Foulkes IO Ellis 2009 Triple negative breast cancer: distinguishing basal and nonbasal subtypes Clin Cancer Res 15 2302 2310 19318481 10.1158/1078-0432.CCR-08-2132 1:CAS:528:DC%2BD1MXjvVWltbs%3D
3. SJ Dawson E Provenzano C Caldas 2009 Triple negative breast cancer: clinical and prognostic implications Eur J Cancer Suppl 1 27 40
4. SC Linn LJ Vant't Veer 2009 Clinical relevance of triple negative breast cancer concept Eur J Cancer 45 Suppl 1 11 26 19775601 10.1016/S0959-8049(09) 70012-7
5. G Viale L Bottiglieri 2009 Pathologic definition of triple negative breast cancer Eur J Cancer 45 Suppl 1 5 10 19775600 10.1016/S0959-8049(09)70011- 5
6. Y Yamamoto M Ibusuki M Nakano 2009 Clinical significance of basal-like subtype in triple-negative breast cancer Breast Cancer 16 260 267 19701681 10.1007/s12282-009-0150-8
7. RC Fernandes JL Bevilacqua IC Soares SA Siqueira L Pires R Hegg FM Carvalho 2009 Coordinated expression of ER, PR, and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas Histopathology 55 346 352 19723150 10.1111/j.1365-2559.2009.03380.x
8. MJ Kim JY Ro SH Ahn HH Kim SB Kim G Gong 2006 Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes Hum Pathol 37 1217 1226 16938528 10.1016/j.humpath.2006.04.015 1:CAS:528:DC%2BD28XovVWrt7k%3D
9. S Cleator W Heller RC Coombes 2009 Triple-negative breast cancer: therapeutic options Lancet Oncol 8 235 244 10.1016/S1470-2045(07)70074-8
10. JE Uhm YH Park SY Yi EY Cho YL Choi SJ Lee MJ Park SH Lee HJ Jun JS Ahn WK Kang K Park YH Im 2009 Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy Int J Cancer 124 1457 1462 19065658 10.1002/ijc.24090 1:CAS:528:DC%2BD1MXisFGgsLg%3D
11. JH Eichhorn 2004 Medullary carcinoma, provocative now as then Semin Diagn Pathol 21 65 73 15074561 10.1053/j.semdp.2003.10.005
12. C Liedtke C Mazouni KR Hess F André A Tordai WF Symmans AM Gonzalez-Angulo B Hennessy M Green M Cristofanilli GN Hortobagyi L Pusztai 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275 1281 18250347 10.1200/JCO.2007.14.4147
13. BG Haffty Q Yang M Reiss T Kearney SA Higgins J Weidhaas L Harris W Hait D Toppmeyer 2006 Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol 24 5652 5657 17116942 10.1200/JCO.2006.06.5664
14. AA Luck AJ Evans AR Green EA Rakha C Paish IO Ellis 2008 The influence of basal phenotype on the metastatic pattern of breast cancer Clin Oncol (R Coll Radiol) 20 40 45 1:STN:280:DC%2BD1c%2FltFWqtA%3D%3D
15. MC Cheang D Voduc C Bajdik S Leung S McKinney SK Chia CM Perou TO Nielsen 2008 Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype Clin Cancer Res 14 1368 1376 18316557 10.1158/1078-0432.CCR-07-1658 1:CAS:528:DC%2BD1cXislSrs7o%3D
16. SE Elsheikh AR Green EA Rakha RM Samaka AA Ammar D Powe JS Reis-Filho IO Ellis 2008 Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype Br J Cancer 99 327 334 18612310 10.1038/sj.bjc.6604463 1:CAS:528:DC%2BD1cXosFWntrY%3D
17. R Dent M Trudeau KI Pritchard WM Hanna HK Kahn CA Sawka LA Lickley E Rawlinson P Sun SA Narod 2007 Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429 4434 17671126 10.1158/1078-0432.CCR-06-3045
18. LA Carey EC Dees L Sawyer L Gatti DT Moore F Collichio DW Ollila CI Sartor ML Graham CM Perou 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329 2334 17438091 10.1158/1078-0432.CCR-06-1109 1:CAS:528:DC%2BD2sXkt1enur0%3D
19. EA Rakha ME El-Sayed AR Green AH Lee JF Robertson IO Ellis 2007 Prognostic markers in triple negative breast cancer Cancer 109 25 32 17146782 10.1002/cncr.22381 1:CAS:528:DC%2BD2sXhtVKrtLY%3D
20. GJ Morris S Naidu AK Topham F Guiles Y Xu P MuCue GF Schwartz PK Park AL Rosenberg K Brill EP Mitchell 2007 Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and end results database Cancer 110 876 884 17620276 10.1002/cncr.22836
21. AA Thike PY Cheok AR Jara-Lazaro B Tan P Tan PH Tan 2010 Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer Mod Pathol 23 123 133 19855377 10.1038/modpathol.2009. 145 1:CAS:528:DC%2BC3cXotlSr
22. EA Rakha IO Ellis 2009 Triple-negative/basal-like breast cancer: review Pathology 41 40 47 19089739 10.1080/00313020802563510
23. LA Carey CM Perou CA Livasy LG Dressler D Cowan K Conway G Karaca MA Troester CK Tse S Edmiston SL Deminh J Geradts MC Cheang TO Nielsen PG Moorman HS Earp RC Millikan 2006 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2492 2502 16757721 10.1001/jama.295.21. 2492 1:CAS:528:DC%2BD28XlsV2rtLw%3D
24. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark Statistics subcommittee of NCI-EORTC working group on cancer diagnostics 2005 Reporting recommendations for tumor marker prognostic studies (REMARK) J Natl Cancer Inst 97 1180 1184 16106022 10.1093/jnci/dji237 1:CAS:528:DC%2BD2MXpsVaks7s%3D
25. J Rhee SW Han DY Oh JH Kim SA Im W Han IA Park DY Noh YJ Bang TY Kim 2008 The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer BMC Cancer 8 307 18947390 10.1186/1471-2407-8-307
26. R Dent WM Hanna M Trudeau E Rawlinson P Sun SA Narod 2009 Pattern of metastatic spread in triple-negative breast cancer Breast Cancer Res Treat 115 423 428 18543098 10.1007/s10549-008-0086-2
27. M Tischkowitz JS Brunet LR Bégin DG Huntsman MC Cheang LA Akslen TO Nielsen WD Foulkes 2007 Use of immunohistochemical markers can refine prognosis in triple negative breast cancer BMC Cancer 7 134 17650314 10.1186/1471-2407-7-134
28. Y Eralp D Derin Y Ozluk E Yavuz N Guney P Saip M Muslumanoglu A Igci S Kücücük M Dincer A Aydiner E Topuz 2008 MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer Ann Oncol 19 669 674 18006896 10.1093/annonc/mdm522 1:STN:280:DC%2BD1c3gsVKlsQ%3D%3D
29. M Schmidt D Hasenclever M Schaeffer D Boehm C Cotarelo E Steiner A Lebrecht W Siggelkow W Weikel I Schiffer-Petry S Gebhard H Pilch 2008 Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer Clin Cancer Res 14 5849 5855 18794096 10.1158/1078-0432.CCR-08-0669 1:CAS:528:DC%2BD1cXhtFaitrjM
30. N Turner A Tutt A Ashworth 2004 Hallmark of 'BRCAness' in sporadic cancers Nat Rev Cancer 4 814 819 15510162 10.1038/nrc1457 1:CAS:528: DC%2BD2cXos1ymu7g%3D
31. LK Diaz VL Cryns WF Symmans 2007 Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice Adv Anat Pathol 14 419 430 18049131 10.1097/PAP.0b013e3181594733 1:CAS:528:DC%2BD2sXhtlCrtb%2FE
32. JE Jaspers S Rottenberg J Jonkers 2009 Therapeutic options for triple-negative breast cancers with defective homologous recombination Biochimica Biophysica Acta 1796 266 280 1:CAS:528:DC%2BD1MXhtFyqsLnE
33. JQ Chen J Russo 2009 ERα-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches Biochimica Biophysica Acta 1796 162 175 1:CAS:528:DC%2BD1MXhtFyqsLnM
34. E Lim F Vaillant D Wu NC Forrest B Pal AH Hart ML Asselin-Labat DE Gyorki T Ward A Partanen F Feleppa LI Huschtscha HJ Thorne kConFab SB Fox M Yan JD French MA Brown GK Smyth JE Visvader GJ Lindeman 2009 Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers Nat Medicine 15 907 915 10.1038/nm.2000 1:CAS:528:DC%2BD1MXpt1Onsro%3D
35. O Dizdar DS Dede N Bulut K Altundag 2008 Dasatinib may also inhibit c-Kit in triple negative breast cancer Breast Cancer Res Treat 107 303 17351742 10.1007/s10549-007-9551-6
36. A Tutt M Robson JE Garber SM Domchek MW Audeh JN Weitzel M Friedlander B Arun N Loman RK Schmutzler A Wardley G Mitchell H Earl M Wickens J Carmichael 2010 Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 235 244 20609467 10.1016/S0140-6736(10)60892-6 1:CAS:528: DC%2BC3cXpt1KktLc%3D
37. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, Rocha C, Ossovskaya V, Sherman B, Bradley C (2009) Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitors in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 27: 793s (abstract # 3)
38. Carey LA, Rugo HS, Marcom PK, Irvin Jr. W, Ferraro M, Burrows E, He X, Perou CM, Winer EP (2008) TBCRC 001. EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 26: 43s (abstract # 1009)